Main Conference - Day 2 (May 13)
6:30am - 7:30am60 minsFree
Fun Run
TIDES Fun Run & Walk
7:15am - 7:45am30 mins
Registration
Registration
Breakfast Spotlight Presentations
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 1
Mastering Manufacturing Challenges in Oligonucleotide Production - From Process Development to Commercial Solutions
- Sven Warhaut, PhD - Vice Head of Manufacturing, BioSpring GmbH
Concurrent Tracks
8:25am - 8:30am5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Co-Chairs' Remarks
- Troels Koch, PhD - CTO & Scientific Advisor, NewCo
- Rubina Parmar, - PhD, Atlas Ventures
8:25am - 8:30am5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairman’s Remarks
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
8:25am - 8:30am5 mins
Peptide Discovery to CMC
Chairman’s Remarks
- Bradley Pentelute, PhD - Professor, Chemistry, Massachusetts Institute of Technology
8:25am - 8:30am5 mins
mRNA & Genome Editing: Technology & Applications
Chairman’s Remarks
- Cecilia Fernández, Ph.D. - Entrepreneur in Residence, Mass General Brigham Ventures
8:25am - 8:30am5 mins
Delivery of Macromolecules
Chairwoman’s Remarks
- Julia Alterman, Ph.D. - Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Chan Medical
8:30am - 9:00am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Conditionally Activated siRNA: Precision RNA Therapeutics through Cell-specific Activation
- Charles Allerson, Ph.D - Chief Technology Officer, Switch Therapeutics
8:30am - 9:00am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Carbohydrate-Free Synthesis of Nucleosides and Nucleoside Analogues
- Robert Britton - Professor, Simon Fraser University
8:30am - 9:00am30 mins
Peptide Discovery to CMC
Novel Peptide Ligands and Therapeutic Applications
- Bradley Pentelute, PhD - Professor, Chemistry, Massachusetts Institute of Technology
8:30am - 9:00am30 mins
mRNA & Genome Editing: Technology & Applications
Transformative LDL Cholesterol Lowering In Vivo CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease
- Linda Burkly - Executive Vice President & Chief Scientific Office, Editas Medicine
8:30am - 9:00am30 mins
Delivery of Macromolecules
TfR-mediated Delivery of Oligonucleotides to the Deep Brain Using the VECTrans® Platform: Initial Learnings and Perspectives
- Guillaume Jacquot, PhD - Program Director, Brain and Tissue Delivery of Oligonucleotides, Vect-Horus
9:00am - 9:30am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Advancing ADAR RNA Editing Technology for Broad Applicability in Precision Medicines
- Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics
9:00am - 9:30am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Biomanufacturing of Modified Nucleoside-5′-triphosphates (5´-NTP) as Building-blocks for the Enzymatic Assembly of Oligonucleotides
- Maryke Fehlau - CTO, BioNukleo
9:00am - 9:30am30 mins
Peptide Discovery to CMC
AI and NCAA to Unlock the Design of Peptide Drugs
- Genwei Zhang, PhD - Head of Peptide Research, XtalPi
9:00am - 9:30am30 mins
mRNA & Genome Editing: Technology & Applications
Toward In Vivo Genetic Medicines with Site-specific Integration of Therapeutically Relevant Genes Via an RNA-only Platform
- Ari Friedland - Vice President of Research, Typewriter Therapeutics
9:00am - 9:30am30 mins
Delivery of Macromolecules
Brain Delivery of Antibody-oligonucleotide Conjugates for CNS Diseases
- Liqun Wang, PhD - Principal Scientist, Brain Targeting Program, Wyss Institute at Harvard University
9:30am - 10:00am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Targeting Fibroblasts in the Heart with Naked ASOs
- Daniel Blessing - Chief Technology Officer & Scientific Co-Founder, HAYA Therapeutics
9:30am - 10:00am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Biocatalytic Approaches to Nucleic Acid Therapeutics Manufacturing
- Sarah Lovelock, Ph.D. - Reader in Biological Chemistry, University of Manchester
9:30am - 10:00am30 mins
Peptide Discovery to CMC
Computational Pipelines for Rational Design of Peptide Macrocycle Therapeutics: Past, Present, and Future
- Vikram Mulligan, PhD - Research Scientist, Flatiron Institute
9:30am - 10:00am30 mins
mRNA & Genome Editing: Technology & Applications
Development of Bespoke Genome Editing Technologies to Treat Disease
- Ben Kleinstiver, PhD - Associate Professor, Massachusetts General Hospital & Harvard Medical School
9:30am - 10:00am30 mins
Delivery of Macromolecules
Leveraging IGF1R Receptor for Antisense Delivery
- Hien Zhao, PhD - Vice President, Neuroscience Research, Ionis Pharmaceuticals
Networking Refreshment Break in Poster and Exhibit Hall
10:00am - 10:45am45 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Refreshment Break in Poster and Exhibit Hall
10:10am - 10:20am10 mins
TIDES Talks in Poster and Exhibit Hall
Bringing Method to the Mid-Size Molecule Manufacturing Madness
- Erina Kamiya - Business Development, Life Industry Division, Inabata America Corporation
10:20am - 10:30am10 mins
TIDES Talks in Poster and Exhibit Hall
A Mild Cleavage and Deprotection Method for RNA Oligonucleotides Synthesized on Universal Supports
- Takaki Habuchi, PhD - Research Associate, Nippon Shokubai
10:30am - 10:40am10 mins
TIDES Talks in Poster and Exhibit Hall
Superior Ligation Solutions for Scalable RNA Manufacturing
- Derek Gauntlett - Vice President, Development, Codexis
10:45am - 11:15am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Late Breaking Presentation
10:45am - 11:15am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Progress on Next Generation siRNA Manufacturing Process Development
- Ligang Zhang, PhD - Vice President, DS Process Development, Alnylam Pharmaceuticals
10:45am - 11:15am30 mins
Peptide Discovery to CMC
Engineering Cyclotides as Orally Bioavailable Inflammatory Cytokine Antagonists
- Karl Dane Wittrup, Ph.D. - C.P. Dubbs Professor in Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology
10:45am - 11:15am30 mins
mRNA & Genome Editing: Technology & Applications
Applying Machine Learning to Identify Differentiated Target Mechanisms and Design Next-Generation Oligonucleotide Therapeutics
- Greg Hoffman, PhD - Chief Scientific Officer, Deep Genomics
10:45am - 11:15am30 mins
Delivery of Macromolecules
Beyond the Standard: Advancing TfR-Mediated Delivery of Oligonucleotide Therapeutics to the CNS
- Felix Schumacher - Program Leader Targeted Therapeutics, Roche
11:15am - 11:45am30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Spatial Structured Oligonucleotides for RNA Therapeutics
- Sudhir Agrawal - President and Founder, Arnay Sciences
11:15am - 11:45am30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
GMP Manufacturing of An Oligonucleotide Containing the Mesylphosphoramidate Chemistry
- Yannick Fillon, PhD - Product Technical Lead, Oligonucleotides, Biogen
11:15am - 11:45am30 mins
Peptide Discovery to CMC
BoltzGen: Toward Universal Binder Design
- Hannes Stärk - PhD Student, CSAIL, MIT
11:15am - 11:45am30 mins
mRNA & Genome Editing: Technology & Applications
Delivery of Gene Writers to Hematopoetic Stem Cells towards an In Vivo Therapy for Sickle Cell Disease
- Jane Wang, PhD - VP and Head of Delivery and Process Devlopment, Tessera Therapeutics
11:15am - 11:45am30 mins
Delivery of Macromolecules
Unlocking the Therapeutic Potential of Oligonucleotides for CNS Disorders Through Targeted Delivery
- Stefano Zanotti, PhD - SVP, Head of Neuromuscular Research, Dyne Therapeutics
11:45am - 12:15pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Improving the Potency and Specificity of RNAi Therapeutics: Carbocyclic DNA and RNA Modifications
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
11:45am - 12:15pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Towards Sustainable Chemical Synthesis for Scalable Oligonucleotide Manufacturing
- Andrew Livingston - Chief Executive Officer, Exactmer
11:45am - 12:15pm30 mins
Peptide Discovery to CMC
ADAPT: An Emerging Platform of Antibody CDR-H3 Peptide Scaffolds in the Landscape of Protein-Protein Interaction Inhibitors
- Stéphane Roche, PhD - Founder and CEO, AdaptBio Therapeutics
11:45am - 12:15pm30 mins
mRNA & Genome Editing: Technology & Applications
Late Breaking Presentation
11:45am - 12:15pm30 mins
Delivery of Macromolecules
Bridging the Divide: Leveraging the Transport Vehicle Platform to Deliver Enzyme, Antibody, and Oligonucleotide-based Therapeutics across the BBB
- Joe Lewcock, PhD - Chief Scientific Officer, Denali Therapeutics
12:15pm - 12:20pm5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Peptide Discovery to CMC
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
mRNA & Genome Editing: Technology & Applications
Transition to Spotlight Presentation Rooms
12:15pm - 12:20pm5 mins
Delivery of Macromolecules
Transition to Spotlight Presentation Rooms
Spotlight Presentations
12:20pm - 12:50pm30 mins
Spotlight Presentation 2
Advances in LC Separations, MS Detection, and Statistical Analyses for Characterizing Oligonucleotide Therapeutics for Advancing New and Generic Drug Development
- Jace Jones, PhD - Associate Professor and Vice Chair for Education Associate Director of the Mass Spectrometry Center Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy
12:20pm - 12:50pm30 mins
Spotlight Presentation 4
OCELOT®: The Open, Unified Software Platform for Modern Oligo Manufacturing
- Stefan Hyde - Automation Manager, Asahi Kasei Bioprocess America
12:50pm - 1:55pm65 mins
Networking Luncheon in Poster and Exhibit Hall
Networking Luncheon in Poster and Exhibit Hall
1:20pm - 1:30pm10 mins
TIDES Talks in Poster and Exhibit Hall
Membrane Applications in Oligonucleotide Synthesis
- Cristina Bertulli, PhD - Vice President of Business, Exactmer Ltd
1:30pm - 1:40pm10 mins
TIDES Talks in Poster and Exhibit Hall
FISTag: A New Tool in the LPPS Arena
- Roberto Profeta - R&D Manager, F.I.S. Fabbrica Italiana Sintetici
1:40pm - 1:50pm10 mins
TIDES Talks in Poster and Exhibit Hall
Innovating Oligonucleotide Production: Enzymatic Fragment Ligation for siRNA
- Wuming Yan - Chief Scientist Oligonucleotides, Asymchem
Concurrent Tracks
1:55pm - 2:00pm5 mins
Oligonucleotide Discovery, Preclinical and Clinical
Chairwoman's Remarks
- Aimee Jackson, PhD - Founder, Jackson Bioscience Consulting
1:55pm - 2:00pm5 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Chairman’s Remarks
- James Powell - SVP, Manufacturing and Boulder Site Head, Novo Nordisk
1:55pm - 2:00pm5 mins
Peptide Discovery to CMC
Co-Chairs’ Remarks
- Tomi Sawyer, PhD - Chief Medicinal Chemistry & Peptide Drug Hunter, Courage Terapeutics; Chief Drug Hunter & President, Maestro Therapeutics
- Charles Johannes, PhD - Founder & President & Chief Scientist, EPOC Scientific LLC
- Ved Srivastava, PhD - CTO, Perpetual Medicines
1:55pm - 2:00pm5 mins
mRNA & Genome Editing: Technology & Applications
Co-Chairs' Remarks
- Seth Alexander, PhD - Director of RNA Technologies, Prime Medicine
- Bradley Pentelute, PhD - Professor, Chemistry, Massachusetts Institute of Technology
1:55pm - 2:00pm5 mins
Delivery of Macromolecules
Chairman’s Remarks
- Stephen Spagnol, PhD - Director, Enabling Technologies, Merck
2:00pm - 2:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Utilization of Oligonucleotides’ Half-Life to Optimize Dosing Regimen for Desirable Efficacy & Reduced CNS Toxicity
- Meena PhD - SVP, Translational DMPK and Clinical Pharmacology, Stoke Therapeutics
2:00pm - 2:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Biocatalytic Synthesis of Oligonucleotides
- Caleb Culy - Senior Principal Chemist, Process Design and Development, Eli Lilly and Company
2:00pm - 2:30pm30 mins
Peptide Discovery to CMC
Breakthroughs in Melanocortin Receptor Targeted Peptide Drug Discovery: There and Back Again!
- Tomi Sawyer, PhD - Chief Medicinal Chemistry & Peptide Drug Hunter, Courage Terapeutics; Chief Drug Hunter & President, Maestro Therapeutics
2:00pm - 2:30pm30 mins
mRNA & Genome Editing: Technology & Applications
Efficient Modification Chemistry for RNA Stabilization and Control
- Eric Kool, Ph.D - Professor of Chemistry, Stanford University
2:00pm - 2:30pm30 mins
Delivery of Macromolecules
Selective Organ-Targeting (SORT) LNP Delivery Platform
- Sakya Mohapatra - Director, Formulation Development, Recode Therapeutics
2:30pm - 3:00pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Investigational RNAi Therapeutics in Development for CNS Diseases
- Vasant Jadhav, PhD - Chief Technology Officer, Alnylam Pharmaceuticals
2:30pm - 3:00pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
New SPOS Support to Drive Next Generation Manufacturing
- Kurt Vagle - Senior Director - Chemical Development RNAi CMC, Novo Nordisk
2:30pm - 3:00pm30 mins
Peptide Discovery to CMC
PN-881: A Next-Generation Oral IL-17 Antagonist Redefining Peptide Immunotherapy
- Ashok Bhandari, PhD - Executive Vice President, Chief Discovery Officer, Protagonist Therapeutics
2:30pm - 3:00pm30 mins
mRNA & Genome Editing: Technology & Applications
Beyond Codons: The Structural and Regulatory Logic Governing mRNA Translation
- Devan Shah - Founder & Chief Executive Officer, RNAV8 Bio
2:30pm - 3:00pm30 mins
Delivery of Macromolecules
Targeted Delivery Platform: Leveraging a Barcoded Platform
- Pierce Ogden, PhD - Co-Founder, CTO and Board Director, Manifold Bio
3:00pm - 3:30pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Cellular Correlates of Oligonucleotide-induced Neurotoxicity
- Benjamin Andreone, PhD - Associate Director, Neuroscience, Atalanta Therapeutics
3:00pm - 3:30pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Rethinking Green Credentials for Oligo Manufacturing
- Louis Diorazio, PhD - Senior Principal Scientist, New Modalities, AstraZeneca
3:00pm - 3:30pm30 mins
Peptide Discovery to CMC
Early Development Strategies for Peptide Therapeutics
- Emel Adaligil, PhD - Executive Director, Chemical Biology and Peptide, Eli Lilly and Company
3:00pm - 3:30pm30 mins
mRNA & Genome Editing: Technology & Applications
Analytical Platform Technologies for mRNA-based Therapeutics and Vaccines
- Andreas Kuhn, PhD - Senior Vice President RNA Biochemistry & CMC Development, BioNTech SE
3:00pm - 3:30pm30 mins
Delivery of Macromolecules
In Vivo Generation of Functional CAR T Cells via Targeted Non-Viral Lipid Nanoparticles Enables Potent Immune Cell Depletion in Non-Human Primates
- Ali Nahvi, Ph.D - Chief Technology Officer, Nava Therapeutics
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Networking Refreshment Break in Poster and Exhibit Hall
Networking Refreshment Break in Poster and Exhibit Hall
3:40pm - 3:50pm10 mins
TIDES Talks in Poster and Exhibit Hall
Cellscript TIDES Talk
3:50pm - 4:00pm10 mins
TIDES Talks in Poster and Exhibit Hall
Cytiva TIDES Talk
4:00pm - 4:10pm10 mins
TIDES Talks in Poster and Exhibit Hall
Cytiva TIDES Talk
4:15pm - 4:45pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
FORCE Platform to Enable Delivery of Oligonucleotides for the Treatment of Neuromuscular Diseases
- Saul Martinez Montero - Senior Director and Head of Oligonucleotide Therapeutics, Dyne Therapeutics
4:15pm - 4:45pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Advancing Sustainability through Innovation in Oligonucleotide Manufacturing
- David Entwistle, PhD - Senior Director, Program & Pipeline Management, Codexis
4:15pm - 4:45pm30 mins
Peptide Discovery to CMC
Navigating Chemical Space to Discover Helicon Peptides for Intracellular Targets
- John McGee - Scientific Co-Founder and Senior Vice President, Platform Technology, Parabilis Medicines
4:15pm - 4:45pm30 mins
mRNA & Genome Editing: Technology & Applications
Self-replicating RNA (srRNA) Vaccines Using Unmodified Bases Show An Expanded Clinical Therapeutic Index and Sustained Immune Responses
- Andrew Geall, PhD - Co-founder and Chief Development Officer, Replicate Bioscience
4:15pm - 4:45pm30 mins
Delivery of Macromolecules
Deep Learning-based Design of Cell-targeting Ligands Enables Functional siRNA Delivery in Multiple Extrahepatic Tissues
- Kyler Lugo, Ph.D - Principal Scientist, Nosis Bio
4:45pm - 5:15pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Activating Anti-tumor Immunity with RNA/DNA Hybrid Agonists of TLR7/8/9
- Art Krieg, MD - CEO, Zola Therapeutics
4:45pm - 5:15pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Enzymatic RNA Synthesis: Accessing Modified gRNA and mRNA & Pushing Efficiency and Scale
- Ella Meyer - Lead of RNA Synthesis, EnPlusOne Bio
4:45pm - 5:15pm30 mins
Peptide Discovery to CMC
Targeting Tumors with Peptide Radioconjugates
- Jefferson Revell, PhD - Principal Scientist, AstraZeneca
4:45pm - 5:15pm30 mins
mRNA & Genome Editing: Technology & Applications
Process and Technology Innovation for RNA Therapeutics
- Telmo Graça, PhD - Head of mRNA Process Development, Lonza
4:45pm - 5:15pm30 mins
Delivery of Macromolecules
Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM™ SC
- Kayal Madhivanan, PhD - Senior Scientist, Arrowhead Pharmaceuticals
5:15pm - 5:45pm30 mins
Oligonucleotide Discovery, Preclinical and Clinical
Targeting the Lung, One Breath at a Time: The Great Promise of Splisense’s ASO Therapeutic Platform to Tackle a Wide Range of Pulmonary Diseases
- Asaf Cohen - SVP, CMC and Operations, Splisense
5:15pm - 5:45pm30 mins
Oligonucleotide Chemistry, Manufacturing and Controls
Enzymatic Approaches to Oligonucleotide Manufacture
- Katharine (Katie) Duncan, PhD - Director, CMC Policy and Advocacy, GlaxoSmithKline (GSK)
5:15pm - 5:45pm30 mins
Peptide Discovery to CMC
Discovery of 225Ac-ETN029: A Peptide-based Radioligand Therapy for the Treatment of DLL3-expressing Solid Tumors
- Melissa Vasbinder, Ph.D - Head of Research, Mariana Oncology
5:15pm - 5:45pm30 mins
mRNA & Genome Editing: Technology & Applications
Enabling Next-Generation mRNA Therapeutics Through a Cell-Based mRNA Design and Manufacturing Platform
- Marian Kupculak, PhD - Co-Founder and Chief Science Officer, Sensible Biotechnologies
5:15pm - 5:45pm30 mins
Delivery of Macromolecules
Late Breaking Presentation
5:45pm - 6:45pm60 mins
Networking Reception in Poster and Exhibit Hall
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.